| Literature DB >> 32184353 |
Nataliya Gorinski1, Daniel Wojciechowski2, Daria Guseva1, Dalia Abdel Galil1, Franziska E Mueller1, Alexander Wirth1, Stefan Thiemann2, Andre Zeug1, Silke Schmidt1, Monika Zareba-Kozioł3, Jakub Wlodarczyk3, Boris V Skryabin4, Silke Glage5, Martin Fischer2, Samer Al-Samir6, Nicole Kerkenberg7, Christa Hohoff8, Weiqi Zhang7, Volker Endeward6, Evgeni Ponimaskin9.
Abstract
Barttin is the accessory subunit of the human ClC-K chloride channels, which are expressed in both the kidney and inner ear. Barttin promotes trafficking of the complex it forms with ClC-K to the plasma membrane and is involved in activating this channel. Barttin undergoes post-translational palmitoylation that is essential for its functions, but the enzyme(s) catalyzing this post-translational modification is unknown. Here, we identified zinc finger DHHC-type containing 7 (DHHC7) protein as an important barttin palmitoyl acyltransferase, whose depletion affected barttin palmitoylation and ClC-K-barttin channel activation. We investigated the functional role of barttin palmitoylation in vivo in Zdhhc7 -/- mice. Although palmitoylation of barttin in kidneys of Zdhhc7 -/- animals was significantly decreased, it did not pathologically alter kidney structure and functions under physiological conditions. However, when Zdhhc7 -/- mice were fed a low-salt diet, they developed hyponatremia and mild metabolic alkalosis, symptoms characteristic of human Bartter syndrome (BS) type IV. Of note, we also observed decreased palmitoylation of the disease-causing R8L barttin variant associated with human BS type IV. Our results indicate that dysregulated DHHC7-mediated barttin palmitoylation appears to play an important role in chloride channel dysfunction in certain BS variants, suggesting that targeting DHHC7 activity may offer a potential therapeutic strategy for reducing hypertension.Entities:
Keywords: Bartter syndrome type IV; barttin; chloride channel ClC-K; enzyme; hypertension; ion channel; kidney metabolism; mouse genetics; nephropathy; palmitoylation; palmitoyltransferase DHHC7; post-translational modification (PTM); renal dysfunction
Mesh:
Substances:
Year: 2020 PMID: 32184353 PMCID: PMC7196637 DOI: 10.1074/jbc.RA119.011049
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157